Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment
1
Issued Date
2022-06-01
Resource Type
ISSN
0125877X
eISSN
22288694
Scopus ID
2-s2.0-85130634078
Pubmed ID
31837211
Journal Title
Asian Pacific Journal of Allergy and Immunology
Volume
40
Issue
2
Start Page
173
End Page
177
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology Vol.40 No.2 (2022) , 173-177
Suggested Citation
Sukharomana M., Udomittipong K., Ruangchira-Urai R., Charuvanij S. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment. Asian Pacific Journal of Allergy and Immunology Vol.40 No.2 (2022) , 173-177. 177. doi:10.12932/ap-050819-0616 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/84981
Title
Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment
Author's Affiliation
Other Contributor(s)
Abstract
Background: Nonspecific interstitial pneumonia (NSIP) is a rare pulmonary complication in systemic juvenile idiopathic arthritis (SJIA). Objective: To present a case with NSIP in SJIA Methods: Case report Results: We report the case of a 4-year-old boy with SJIA complicated by macrophage activation syndrome (MAS) refractory to conventional therapy, and who later developed NSIP confirmed by high-resolution computerized tomography of the chest and lung histopathology. The patient received tocilizumab, a monoclonal antibody to interleukin-6 receptor, to control his disease. Data relating to tocilizumab treatment of NSIP in refractory SJIA is limited. Conclusions: The data from this case report suggests that NSIP could be a pulmonary complication of SJIA complicated by MAS that is refractory to conventional therapy. Early initiation of tocilizumab should be considered to achieve disease remission in this pediatric patient population.